Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis of oxidative stress biomarkers in older adults with T2DM or Parkinson's disease

Systematic review and meta-analysis of oxidative stress biomarkers in older adults with T2DM or Park…
Photo by CDC / Unsplash
Key Takeaway
Note markedly elevated oxidative stress biomarkers in T2DM and PD, but interpret findings cautiously due to high heterogeneity.

This systematic review and meta-analysis assessed oxidative stress biomarkers in serum, plasma, or leukocytes across 7,521 human subjects aged ≥ 50 years, comprising 3,522 with type 2 diabetes mellitus (T2DM), 722 with Parkinson's disease (PD), and 3,277 controls. The primary outcomes measured standardized differences (Hedges' g) for F2-isoprostanes and 8-OHdG to compare patient groups against controls.

In the T2DM population, F2-isoprostanes were markedly elevated with an effect size of 1.60 (95% CI: 0.95-2.25). Similarly, 8-OHdG levels were markedly elevated in T2DM, showing an effect size of 2.64 (95% CI: 2.13-3.14). When examining T2DM patients with nephropathy, 8-OHdG indicated extreme oxidative stress with an effect size of 5.24.

In the PD cohort, 8-OHdG was moderately elevated with an effect size of 0.78 (95% CI: 0.18-1.39; p = 0.011). Conversely, F2-isoprostanes in PD were not significantly elevated, with an effect size of 0.47 (95% CI: -0.43-1.38). The authors noted high heterogeneity in T2DM (I > 90%), reflecting methodological variability.

Safety data, including adverse events and tolerability, were not reported. The findings suggest associations between specific biomarkers and disease states but do not establish causality. Practice relevance regarding clinical utility remains uncertain given the observational nature of the data and reported limitations.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedDec 2026
View Original Abstract ↓
BACKGROUND: Oxidative stress is central to type 2 diabetes mellitus (T2DM) and Parkinson's disease (PD). However, the utility of biomarkers for lipid peroxidation (F2-isoprostanes) and DNA damage (8-OHdG) in the comorbidity of PD and T2DM remains unclear. METHODS: We conducted a systematic review and meta-analysis of 54 unique studies of human subjects aged ≥ 50 years ( = 7,521: 3,522 with T2DM, 722 with PD, and 3,277 controls), measuring biomarkers in serum, plasma, or leukocytes. Mixed-effects models quantified standardized differences (Hedges' g) across subgroups. RESULTS: In T2DM, F2-isoprostanes ( = 1.60, 95% CI: 0.95-2.25) and 8-OHdG ( = 2.64, 95% CI: 2.13-3.14) were markedly elevated ( < 0.001). Stronger effects were observed in younger cohorts and serum/plasma samples, with complications like nephropathy exhibiting extreme oxidative stress ( = 5.24). In PD, 8-OHdG was moderately elevated ( = 0.78, 95% CI: 0.18-1.39;  = 0.011), particularly in randomized controlled trials and plasma samples, whereas F2-isoprostanes were not significantly elevated ( = 0.47, 95% CI: -0.43-1.38). High heterogeneity in T2DM (I > 90%) reflected methodological variability. CONCLUSION: Distinct profiles - both markers elevated in T2DM but only 8-OHdG in PD - underscore 8-OHdG's potential in PD-T2DM comorbidity. Future research should focus on standardized assays, multi-compartmental or multi-modal sampling, and longitudinal studies to clarify mechanisms and therapeutic targets.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.